Polycyclo Ring System Having The Five-membered Hetero Ring As One Of The Cyclos Patents (Class 548/126)
-
Publication number: 20140243366Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: May 1, 2014Publication date: August 28, 2014Applicant: CalciMedica, Inc.Inventors: Jeffrey P. WHITTEN, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
-
Publication number: 20140243334Abstract: This invention provides compounds of formula (I): wherein R1a, R1b, R1c, R2a, R2b, R2c, and R2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.Type: ApplicationFiled: May 5, 2014Publication date: August 28, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Emily F. Calderwood, Dylan B. England, Alexandra E. Gould, Sean J. Harrison, Liting Ma
-
Patent number: 8802975Abstract: Provided are compounds with a donor moiety, a first acceptor moiety and a second acceptor moiety, as shown by Formula (I): With the unique molecular design, compounds of Formula (I) can provide a desirable power conversion efficiency. Moreover, this invention also provides organic thin-film solar cells comprising the above-mentioned compounds.Type: GrantFiled: January 3, 2012Date of Patent: August 12, 2014Inventors: Ken-Tsung Wong, Hao-Wu Lin, Li-Yen Lin, Francis Lin, Yi-Hong Chen, Shi-Wen Chiu
-
Publication number: 20140221663Abstract: Process for the preparation of a benzohetero[1,3]diazole compound disubstituted with heteroaryl groups which comprises reacting at least one benzohetero[1,3]diazole compound disubstituted with at least one heteroaryl compound. Said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can be advantageously used in the construction of luminescent solar concentrators (LSC). Furthermore, said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can be advantageously used in the construction of photovoltaic devices such as, for example, photovoltaic cells, photovoltaic modules, solar cells, solar modules, on both a rigid and flexible support. Said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can also be advantageously used as a precursor of monomeric units in the preparation of semiconductor polymers.Type: ApplicationFiled: August 1, 2012Publication date: August 7, 2014Applicant: Eni S.P.A.Inventors: Giuliana Schimperna, Gabriele Bianchi
-
Patent number: 8772321Abstract: Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.Type: GrantFiled: December 14, 2011Date of Patent: July 8, 2014Assignee: National Defense Medical CenterInventors: Hsu-Shan Huang, Tsung-Chih Chen, Tai-Lung Cha
-
Patent number: 8759539Abstract: Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.Type: GrantFiled: November 11, 2009Date of Patent: June 24, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Jiafang He, John Bawiec, Weiguo Liu, Gui-Bai Liang, Lihu Yang
-
Publication number: 20140166987Abstract: Conjugated polymers and small molecules including the nonplanar aromatic 1,6-methano[10]annulene ring structure along with aromatic subunits, such as diketopyrrolopyrrole, and 2,1,3-benzothiadiazole, substituted with alkyl chains in a “Tail In,” “Tail Out,” or “No Tail” regiochemistry are disclosed.Type: ApplicationFiled: December 14, 2012Publication date: June 19, 2014Applicant: The Johns Hopkins UniversityInventors: John D. Tovar, Benjamin C. Streifel, Patricia A. Peart
-
Publication number: 20140148489Abstract: The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: ApplicationFiled: April 17, 2012Publication date: May 29, 2014Applicant: UCB PHARMA, S.A.Inventors: Laurent Provins, Yannick Quesnel
-
Publication number: 20140142308Abstract: Receptor type oligothiopene compounds, methods of preparing the compounds, and use of the compounds in photoelectric materials.Type: ApplicationFiled: March 27, 2012Publication date: May 22, 2014Applicant: NANKAI UNIVERSITYInventors: Yongsheng Chen, Xiangjian Wan, Yongsheng Liu, Zhi Li, Jiaoyan Zhou, Fei Wang, Guangrui He, Guankui Long
-
Patent number: 8722887Abstract: This invention concerns compounds of the general formula (1): and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description.Type: GrantFiled: February 16, 2010Date of Patent: May 13, 2014Assignee: Abbvie Bahamas, Ltd.Inventors: Arnold Van Loevezijn, Wouter I. Iwema Bakker, Hiskias G. Keizer, Jan Zorgdrager, Martina A. W. Van Der Neut, Cornelis G. Kruse
-
Publication number: 20140100213Abstract: This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.Type: ApplicationFiled: November 4, 2013Publication date: April 10, 2014Applicant: GlaxoSmithKline LLCInventors: Nicholas David Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan Michael Chergurovich, Terence John Kiesow, Cynthia Ann Parrish, Alexander Joseph Reif, Kenneth Wiggall
-
Publication number: 20140100242Abstract: Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.Type: ApplicationFiled: September 17, 2013Publication date: April 10, 2014Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Bonnie Bassler, Lee Swem
-
Publication number: 20140084217Abstract: A polymer compound comprising a constituent unit represented by the formula (1), the formula (2), the formula (3) or the formula (4) can be utilized for producing an organic film solar battery showing high open end voltage: (in the formulae (1) to (4), Ar1 represents a tri-valent aromatic carbocyclic group or a tri-valent aromatic heterocyclic group. Ar2 represents a tetra-valent aromatic carbocyclic group or a tetra-valent aromatic heterocyclic group. Z represents —O—, —S—, —C(C?O)—, —S(?O)—, —SO2—, —Si(R)2—, —N(R)—, —B(R)—, —P(R)— or —P(?O)(R)—. R represents a hydrogen atom, a halogen atom or a mono-valent group.).Type: ApplicationFiled: June 1, 2012Publication date: March 27, 2014Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Kenichiro Ohya, Ken Yoshimura
-
Patent number: 8680159Abstract: Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.Type: GrantFiled: September 22, 2011Date of Patent: March 25, 2014Assignee: Gruenenthal GmbHInventors: Melanie Reich, Stefan Schunk, Ruth Jostock, Jean De Vry, Christa Kneip, Tieno Germann, Michael Engels
-
Publication number: 20140061538Abstract: The invention relates to novel polymers containing one or more benzo[1,2-b:4,5-b?]dithiophene-4,8-dione repeating units, methods for their preparation and monomers used therein, blends, mixtures and formulations containing them, the use of the polymers, blends, mixtures and formulations as semiconductor in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers, blends, mixtures or formulations.Type: ApplicationFiled: April 23, 2012Publication date: March 6, 2014Applicant: MERCK PATENT GMBHInventors: Nicolas Blouin, William Mitchell, Amy Topley, Steven Tierney
-
Patent number: 8664249Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.Type: GrantFiled: February 1, 2013Date of Patent: March 4, 2014Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Gideon Shapiro, Richard Chesworth
-
Publication number: 20140053905Abstract: This disclosure relates to a photovoltaic cell that includes a first electrode, a second electrode, and a photoactive layer disposed between the first and second electrodes. The photoactive layer includes a photoactive polymer containing a first monomer repeat unit, which contains a moiety of formula (1): in which A and R are defined in the specification.Type: ApplicationFiled: October 9, 2013Publication date: February 27, 2014Applicant: Merck Patent GmbHInventors: Paul Byrne, Li Wen, David P. Waller, Taizoon Canteenwala, Patrick Foyle, Edward Jackson
-
Publication number: 20140038942Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.Type: ApplicationFiled: February 10, 2012Publication date: February 6, 2014Applicants: Merck Sharp & Dohme B.V., Merck Sharp & Dohme Corp.Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
-
Publication number: 20140027746Abstract: The present invention relates to compounds of the general formula (I) The present invention also relates to a process for the preparation of such compounds, the compounds obtainable by this process, the use of these compounds, semiconducting layers and electronic components.Type: ApplicationFiled: January 12, 2012Publication date: January 30, 2014Applicant: Heraeus Precious Metals GMBH & Co. KGInventors: Eva Nutz, Timo Meyer-Friedrichsen, Andreas Elschner, Wilfried Lövenich, Sergei Anatolievich Ponomarenko, Juriy N. Luponosow
-
Patent number: 8637556Abstract: Provided herein are compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.Type: GrantFiled: January 15, 2010Date of Patent: January 28, 2014Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Georgetown UniversityInventors: Steven J. Metallo, Edward V. Prochownik, Ariele Viacava Follis
-
Publication number: 20140024636Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.Type: ApplicationFiled: March 30, 2012Publication date: January 23, 2014Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Ki Young Kim, Jin Hee Ahn, Seung Kyu Kang, Sang Dal Rhee, Myung Ae Bae, Sung Hoon Ahn, Hee Youn Kim, Won Hoon Jung, Nam Sook Kang
-
Patent number: 8633237Abstract: The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.Type: GrantFiled: April 8, 2010Date of Patent: January 21, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Kevin J. Gillen, Jonathan Gillespie, Craig Jamieson, John K. F. MacLean, Elizabeth M. Moir, Zoran Rankovic
-
Publication number: 20140010762Abstract: An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hCE-1 in the cells independently of the amount of hCE-2 and/or hCE-3 in the cells, said imaging agent being a covalent conjugate of (a) an imaging agent and (b) an alpha mono- or di-substituted amino acid ester, wherein (a) is directly linked to (b), or (a) is indirectly linked to (b) by a linker radical, and wherein said direct or indirect linkage is via the amino group of (b), and wherein the amino group is not directly linked to a carbonyl group, and wherein the said alpha mono- or di-substituted amino acid ester part is selectively hydrolysable to the corresponding carboxylic acid part by the intracellular carboxylesterase enzyme hCE-1 relative to the intracellular enzymes hCE-2 or hCE-3.Type: ApplicationFiled: December 16, 2011Publication date: January 9, 2014Applicant: Chroma Therapeutics LtdInventor: Margaret Struthers Drummond
-
Patent number: 8592464Abstract: The present invention relates to nitric oxide furoxan derivative compounds which showed to be active in the treatment of tumors. In addition, they may be used as adjuvants in cancer immunotherapy.Type: GrantFiled: January 15, 2010Date of Patent: November 26, 2013Assignees: Humanitas Mirasole S.p.A., Istituto Oncologico Veneto IRCCSInventors: Antonella Viola, Enzo Bronte, Marco Crosetti, Loretta Lazzarato, Roberta Fruttero, Alberto Gasco
-
Patent number: 8580956Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.Type: GrantFiled: May 28, 2008Date of Patent: November 12, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Zhaoning Zhu, William J. Greenlee, Zhong-Yue Sun, Gioconda Gallo, Ruo Xu, Xianhai Huang, Xiaohong Zhu
-
Publication number: 20130296322Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: July 8, 2013Publication date: November 7, 2013Applicant: THERAVANCE, INC.Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
-
Publication number: 20130289028Abstract: A heterocyclic fused anthraquinone derivatives, which is represented by a formula (I): wherein R1 is a substituent being one selected from a group consisting of hydrogen, halogens, aminoalkyl group, sulfoalkyl group, haloalkyl group, piperazino group, sulfonyl group, morpholino group, alkali group or one substituent represented by a formula (II): wherein R2 is amino group, oxyl group or a thiol group. In the meantime, a method for manufacturing the above-mentioned heterocyclic fused anthraquinone derivatives and a pharmaceutical composition using thereof are also disclosed here.Type: ApplicationFiled: March 1, 2013Publication date: October 31, 2013Applicant: NATIONAL DEFENSE MEDICAL CENTERInventors: Hsu-Shan HUANG, Yu-Ru LEE, Tsung-Chih CHEN
-
Patent number: 8563550Abstract: There is provided compounds of formula (I), wherein Z, M, R1, X, R2, R3 and B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PIM family kinase or PI3-K) is desired and/or required, and particularly in the treatment of cancer.Type: GrantFiled: September 29, 2008Date of Patent: October 22, 2013Inventors: Paolo Pevarello, Ana Maria Garcia Collazo, Ana Belen Garcia Garcia
-
Publication number: 20130256647Abstract: Aspects of the present invention can provide a novel phenanthrothiadiazole compound with the lowest excited triplet level T1 that is high, the phenanthrothiadiazole compound being capable of forming a stable amorphous film. Furthermore, aspects of the present invention can provide an organic light-emitting device having high luminous efficiency and a low driving voltage. Aspects of the present invention provide a phenanthrothiadiazole compound represented by one of general formulae [1] to [3] according to Claim 1.Type: ApplicationFiled: November 10, 2011Publication date: October 3, 2013Applicant: CANON KABUSHIKI KAISHAInventors: Yosuke Nishide, Naoki Yamada, Akihito Saitoh
-
Publication number: 20130247989Abstract: Small organic molecule chromophores containing a benzo[c][1,2,5]thiadiazole with an electron-withdrawing substituent W in the 5-position (5BTH), benzo[c][1,2,5]oxadiazole with an electron-withdrawing substituent W in the 5-position (5BO), 2H-benzo[d][1,2,3]triazole (5BTR) with an electron-withdrawing substituent W in the 5-position (5BTR), 5-fluorobenzo[c][1,2,5]thiadiazole (FBTH), 5-fluorobenzo[c][1,2,5]oxadiazole (FBO), or 5-fluoro-2H-benzo[d][1,2,3]triazole (FBTR) core structure are disclosed. Such compounds can be used in organic heterojunction devices, such as organic small molecule solar cells and transistors.Type: ApplicationFiled: March 13, 2013Publication date: September 26, 2013Applicant: The Regents of the University of CaliforniaInventors: Guillermo C. BAZAN, Thomas S. Van Der Poll, Thuc-Quyen Nguyen, John Love
-
Patent number: 8541596Abstract: Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.Type: GrantFiled: April 21, 2011Date of Patent: September 24, 2013Assignee: Probiodrug AGInventors: Ulrich Heiser, Daniel Ramsbeck, Torsten Hoffmann, Livia Boehme
-
Patent number: 8540521Abstract: Disclosed are benzoxazole-based compounds, kits, and methods of producing and using the described compounds in fluorescence-based detection of analytes (e.g., metal ions). Also disclosed are uses of benzoxazole-based compounds as ratiometric metal ion indicators.Type: GrantFiled: December 29, 2009Date of Patent: September 24, 2013Assignee: Life Technologies CorporationInventors: Kyle Gee, Vladimir Martin
-
Publication number: 20130245072Abstract: A compound of formula (I): wherein A1, A2, A3, A4, A5, G1, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode and mollusc pests.Type: ApplicationFiled: May 10, 2013Publication date: September 19, 2013Applicant: SYNGENTA CORP PROTECTION LLCInventors: Peter Renold, Jerome Yves Cassayre, Jagadish Pabba, Myriem El Qacemi, Thomas Pitterna
-
Publication number: 20130245025Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: January 3, 2013Publication date: September 19, 2013Applicant: CalciMedica, Inc.Inventors: Gonul Velicelebi, Kenneth A. Stauderman, Jeffrey P. Whitten, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
-
Patent number: 8536157Abstract: The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them.Type: GrantFiled: April 14, 2008Date of Patent: September 17, 2013Assignee: The University of MelbourneInventors: Alastair Stewart, Martin Banwell, Brenda Leung, Anu Augustine, Jacki Kitching, Thomasz Bilski
-
Publication number: 20130217732Abstract: This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.Type: ApplicationFiled: September 27, 2011Publication date: August 22, 2013Inventor: Chris P. Miller
-
Patent number: 8513290Abstract: Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.Type: GrantFiled: June 7, 2012Date of Patent: August 20, 2013Assignees: Colorado State University Research Foundation, Dana-Farber Cancer Institute, Inc., University of Notre Dame du LacInventors: Robert M. Williams, James E. Bradner, Albert Bowers, Tenaya Newkirk, Olaf G. Wiest
-
Publication number: 20130204007Abstract: Luminescent solar concentrator (LSC) includes at least one disubstituted benzothiadiazole compound having general formula (I): wherein: R1, R2, R3, R4, R5, R6 and R7, equal to or different from each other, represent a hydrogen atom; or they are selected from linear or branched C1-C20, preferably C1-C10, alkyl groups, cycloalkyl groups optionally substituted, aryl groups optionally substituted, linear or branched C1-C20, preferably C1-C10, alkoxyl groups, optionally substituted; or R1 and R2, or R3 and R4, or R5 and R6, or R6 and R7 can be optionally bound to each other so as to form, together with the carbon atoms to which they are bound, a cycle or a polycyclic system containing from 3 to 14, preferably from 4 to 6 carbon atoms, saturated, unsaturated, or aromatic, optionally containing one or more heteroatoms.Type: ApplicationFiled: August 8, 2012Publication date: August 8, 2013Applicant: Eni S.p.A.Inventors: Samuele Santarelli, Roberto Fusco, Gabriele Bianchi
-
Publication number: 20130203593Abstract: This document discloses molecules having the following formulas (“Formula One” & “Formula Two” and “Formula Three”) The Ar1, Het, Ar2, R1, R2, R3, R4, and R5 are further described herein.Type: ApplicationFiled: January 23, 2013Publication date: August 8, 2013Applicant: Dow AgroSciences LLCInventor: Dow AgroSciences LLC
-
Publication number: 20130203592Abstract: This document discloses molecules having the following formulas (“Formula One” &“Formula Two” and “Formula Three”) The Ar1, Het, Ar2, R1, R2, R3, R4, and R5 are further described herein.Type: ApplicationFiled: January 22, 2013Publication date: August 8, 2013Applicant: Dow AgroSciences LLCInventor: Dow AgroSciences LLC
-
Publication number: 20130200352Abstract: An electroluminescent device (20) having a first layer comprising a fluorinated first organic compound with one or more fluorene residues and soluble in a fluorinated solvent, the first layer being adjacent to a second layer having second organic compound that is insoluble in a fluorinated solvent, and methods and materials for making said device.Type: ApplicationFiled: September 2, 2011Publication date: August 8, 2013Applicant: CAMBRIDGE DISPLAY TECHNOLOGY, LTD.Inventor: Jonathan Pillow
-
Publication number: 20130203818Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: April 27, 2011Publication date: August 8, 2013Applicant: CALCIMEDICA, INC.Inventors: Jeffrey P. Whitten, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
-
Publication number: 20130190351Abstract: This invention relates to bicyclic amide compounds, pharmaceutical compositions and methods for use in the prevention and treatment of a variety of conditions and/or disease states including cerebral insufficiency, through the enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors as defined herein. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in other disorders wherein a deficiency in neurotrophic factors is implicated, as well as other disorders as described herein.Type: ApplicationFiled: July 25, 2012Publication date: July 25, 2013Applicant: CORTEX PHARMACEUTICALS, INC.Inventors: Rudolf Mueller, Leslie Street
-
Publication number: 20130184258Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: October 26, 2012Publication date: July 18, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventor: Vertex Pharmaceuticals Incorporated
-
Publication number: 20130165485Abstract: A compound of formula (I): where A, B, C, G, m, n, o, p, R1, R2, R3, R4, R5, R6, X, R7, R8, R9, R10 and R11 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising the compounds of formula (I) and to methods of using the compounds of formula (I) to control insect, acarine, nematode and mollusc pests.Type: ApplicationFiled: February 20, 2013Publication date: June 27, 2013Applicant: Syngenta Crop Protection LLCInventors: Jerome Yves Cassayre, Peter Renold, Vladimir Bobosik, Myriem El Qacemi, Anne Jacqueline Dalencon, Werner Zambach, Christopher Richard Godfrey, Thomas Pitterna, Pierre Joseph Jung, Jagadish Pabba
-
Publication number: 20130161567Abstract: The invention relates to novel polymers containing repeating units based on benzo[2,1,3]thiadiazole-5,6-dicarboxylic acid bis-ester, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers.Type: ApplicationFiled: August 5, 2011Publication date: June 27, 2013Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: William Mitchell, Steven Tierney, Nicolas Blouin, Frank Egon Meyer, Miguel Carrasco-Orozco
-
Publication number: 20130165486Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.Type: ApplicationFiled: February 1, 2013Publication date: June 27, 2013Applicant: ENVIVO PHARMACEUTICALS, INC.Inventor: ENVIVO PHARMACEUTICALS, INC.
-
Publication number: 20130157403Abstract: A species for use, for example, in a charge transfer layer of a photovoltaic device, the species comprising an acceptor group to which is fused a tuning group. The species can be a small molecule, polymer or oligomer, and monomers for producing said polymer, photovoltaic devices comprising said species, and methods for producing said device, are also provided.Type: ApplicationFiled: September 2, 2011Publication date: June 20, 2013Applicant: CAMBRIDGE DISPLAY TECHNOLOGY LIMITEDInventors: Sheena Zuberi, Tania Zuberi
-
Patent number: 8466149Abstract: In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11?-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11?-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.Type: GrantFiled: August 12, 2008Date of Patent: June 18, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Craig D. Boyle, Samuel Chackalamannil, Unmesh Shah, Claire M. Lankin
-
Patent number: 8450497Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R0, R1, R2, R3, R4 and a are defined herein.Type: GrantFiled: June 10, 2010Date of Patent: May 28, 2013Assignee: Janssen Pharmaceutica, NVInventors: Mark J. Macielag, Mingde Xia, Xiaoqing Xu